Salicylate •Phenanthroline Copper (II) Complex Induces Apoptosis in Triple-negative Breast Cancer Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Apr 19

PMID 28415735

Citations 3

Authors

Limei Fan

Muyou Tian

Yunyi Liu

Ying Deng

Zhengkai Liao

Jinhua Xu

Affiliations

Soon will be listed here.

Abstract

In this study, we investigated anti-tumor activity and associated molecular mechanism of action of Salicylate ●Phenanthroline Copper (II) Complex in triple-negative breast cancer. Salicylate ●Phenanthroline Copper (II) Complex inhibited the growth of four breast cancer cell lines (MCF-7, T47D, MDA-MB-231 and BT-20) and induced apoptosis in a concentration-dependent manner. The effect was more profound in MDA-MB-231 and BT-20 triple-negative breast cancer cell lines. Western blot showed that the expression of the apoptosis-related protein Bcl-2, Bcl-xl and survivin was significantly reduced in MDA-MB-231 after treatment with Salicylate ●Phenanthroline Copper (II) Complex. In vivo, Salicylate ●Phenanthroline Copper (II) Complex administration significantly attenuated tumor growth of MDA-MB-231 xenografts, and the expression levels of Bcl-2, Bcl-xL and survivin were reduced as measured by immunohistochemical staining. These data suggest that Salicylate ●Phenanthroline Copper (II) Complex is a promising novel therapeutic drug for triple-negative breast cancer and warrants further study.

Citing Articles

Copper (II) complex of salicylate phenanthroline induces the apoptosis of colorectal cancer cells, including oxaliplatin‑resistant cells.

Liu Z, Fan L, Niu D, Chen M, Zhang W, Liu Y Oncol Rep. 2023; 50(3).

PMID: 37503758 PMC: 10394729. DOI: 10.3892/or.2023.8607.

Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells.

Chen H, Wang D, Fan L, Liu Z, Zhang W, Xu J Sci Rep. 2022; 12(1):4545.

PMID: 35296801 PMC: 8927491. DOI: 10.1038/s41598-022-08704-0.

Apoptotic effect of novel pyrazolone-based derivative [Cu(PMPP-SAL)(EtOH)] on HeLa cells and its mechanism.

Reheman D, Zhao J, Guan S, Xu G, Li Y, Sun S Sci Rep. 2020; 10(1):18235.

PMID: 33106514 PMC: 7588458. DOI: 10.1038/s41598-020-75173-8.

References

Sorenson J, Wangila G . Co-treatment with copper compounds dramatically decreases toxicities observed with cisplatin cancer therapy and the anticancer efficacy of some copper chelates supports the conclusion that copper chelate therapy may be markedly more effective and.... Curr Med Chem. 2007; 14(14):1499-503. DOI: 10.2174/092986707780831041. View

Chen X, Duan N, Zhang C, Zhang W . Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies. J Cancer. 2016; 7(3):314-23. PMC: 4747886. DOI: 10.7150/jca.13332. View

Hamy A, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretiere J . BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2016; 159(3):499-511. DOI: 10.1007/s10549-016-3961-2. View

Altieri D . Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2007; 8(1):61-70. DOI: 10.1038/nrc2293. View

Cuzick J, Otto F, Baron J, Brown P, Burn J, Greenwald P . Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009; 10(5):501-7. DOI: 10.1016/S1470-2045(09)70035-X. View

von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M . Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014; 15(7):747-56. DOI: 10.1016/S1470-2045(14)70160-3. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

OConnor M, Kellett A, McCann M, Rosair G, McNamara M, Howe O . Copper(II) complexes of salicylic acid combining superoxide dismutase mimetic properties with DNA binding and cleaving capabilities display promising chemotherapeutic potential with fast acting in vitro cytotoxicity against cisplatin sensitive and.... J Med Chem. 2012; 55(5):1957-68. DOI: 10.1021/jm201041d. View

Basu A, Haldar S . Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett. 2003; 538(1-3):41-7. DOI: 10.1016/s0014-5793(03)00131-5. View

10.

Mita A, Mita M, Nawrocki S, Giles F . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16):5000-5. DOI: 10.1158/1078-0432.CCR-08-0746. View

11.

Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C . Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. 2015; 6(29):26560-74. PMC: 4694936. DOI: 10.18632/oncotarget.5306. View

12.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

13.

Upreti M, Galitovskaya E, Chu R, Tackett A, Terrano D, Granell S . Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem. 2008; 283(51):35517-25. PMC: 2602892. DOI: 10.1074/jbc.M805019200. View

14.

de Necochea-Campion R, Chen C, Mirshahidi S, Howard F, Wall N . Clinico-pathologic relevance of Survivin splice variant expression in cancer. Cancer Lett. 2013; 339(2):167-74. PMC: 3775917. DOI: 10.1016/j.canlet.2013.06.007. View

15.

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B . Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2002; (30):96-102. DOI: 10.1093/oxfordjournals.jncimonographs.a003469. View

16.

Deveraux Q, Reed J . IAP family proteins--suppressors of apoptosis. Genes Dev. 1999; 13(3):239-52. DOI: 10.1101/gad.13.3.239. View

17.

Xu J, Prosperi J, Choudhury N, Olopade O, Goss K . β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One. 2015; 10(2):e0117097. PMC: 4319896. DOI: 10.1371/journal.pone.0117097. View

18.

Sorenson J . Inflammatory diseases and copper. J R Soc Med. 2010; 77(3):256. PMC: 1439876. View

19.

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View

20.

Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V . The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014; 144(2):223-32. DOI: 10.1007/s10549-014-2876-z. View